8-K
filed February 15, 2024, 6:59 PM ET
ticker IRWD
CIK 0001446847
earnings
confidence high
sentiment negative
materiality 0.85
Ironwood reports FY2023 GAAP net loss of $1.0B; LINZESS sales $1.1B (+7%)
IRONWOOD PHARMACEUTICALS INC
2023-FY EPS reported
-$6.45
revenue$442,735,000
- FY2023 total revenue $442.7M; LINZESS collaboration revenue $430M; Q4 revenue $117.6M.
- FY2023 GAAP net loss attributable to Ironwood $1.002B ($6.45 diluted loss/share), vs FY2022 net income $175M.
- LINZESS U.S. net sales $1.1B (+7% YoY), prescription demand +10% YoY; pediatric IBS-C approval in June 2023.
- Expects topline STARS Phase 3 study of apraglutide in SBS-IF in March 2024; CNP-104 Phase 2 data in Q3 2024.
- FY2023 adjusted EBITDA loss $884.8M (includes impairment), vs positive $251.8M in FY2022.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IRONWOOD PHARMACEUTICALS INC reported the quarter ended December 31, 2023 results: revenue $ 117,553, net income (1,087), EPS (0.01).
- Period
- the quarter ended December 31, 2023
- Revenue
- $ 117,553
- Net income
- (1,087)
- EPS
- (0.01)
- Result
- reported results
Exact text from the filing
Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IRONWOOD PHARMACEUTICALS INC reported the year ended December 31, 2023 results: revenue $ 442,735, net income (1,002,239), EPS (6.45).
- Period
- the year ended December 31, 2023
- Revenue
- $ 442,735
- Net income
- (1,002,239)
- EPS
- (6.45)
- Result
- reported results
Exact text from the filing
Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.